Page 146 - IJB-10-1

International Journal of Bioprinting Bioprinting organoids for toxicity testing

Ethics approval and consent to participate 10. Palikuqi B, Nguyen DT, Li G, et al. Adaptable
haemodynamic endothelial cells for organogenesis and
Not applicable. tumorigenesis. Nature. 2020;585(7825):426-432.
doi: 10.1038/s41586-020-2712-z
Consent for publication
11. Meng Q, Liang C, Hua J, et al. A miR-146a-5p/TRAF6/NF-
Not applicable. kB p65 axis regulates pancreatic cancer chemoresistance:
Functional validation and clinical significance. Theranostics.
Availability of data 2020;10(9):3967-3979.
doi: 10.7150/thno.40566
Not applicable.
12. Xu Y, Song D, Wang X. 3D bioprinting for pancreas engineering/
References manufacturing. Polymers (Basel). 2022;14(23):5143.
doi: 10.3390/polym14235143
1. Yang J, Xu J, Zhang B, et al. Ferroptosis: At the crossroad 13. Zhao T, Xiao D, Jin F, et al. ESE3-positive PSCs drive
of gemcitabine resistance and tumorigenesis in pancreatic pancreatic cancer fibrosis, chemoresistance and poor
cancer. Int J Mol Sci. 2021;22(20):10944. prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling
doi: 10.3390/ijms222010944 axis. Br J Cancer. 2022;127(8):1461-1472.
doi: 10.1038/s41416-022-01927-y
2. Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition
(EMT) and cancer stem cells: Implication for treatment 14. Grasso C, Jansen G, Giovannetti E. Drug resistance in
resistance in pancreatic cancer. Mol Cancer. 2017;16(1):52. pancreatic cancer: Impact of altered energy metabolism.
doi: 10.1186/s12943-017-0624-9 Crit Rev Oncol Hematol. 2017;114: 139-152.
doi: 10.1016/j.critrevonc.2017.03.026
3. Sherman MH, Beatty GL. Tumor microenvironment in
pancreatic cancer pathogenesis and therapeutic resistance. 15. Niedźwiedzka-Rystwej P, Wołącewicz M, Cywoniuk P,
Annu Rev Pathol. 2023;18: 123-148. et al. Transformation of stem cells used in the 3D bioprinting
doi: 10.1146/annurev-pathmechdis-031621-024600 process as a personalized treatment method for type 1
diabetes. Arch Immunol Ther Exp (Warsz). 2020;68(2):13.
4. Masuo K, Chen R, Yogo A, et al. SNAIL2 contributes to doi: 10.1007/s00005-020-00578-2
tumorigenicity and chemotherapy resistance in pancreatic
cancer by regulating IGFBP2. Cancer Sci. 2021;112(12):4987- 16. Hennig A, Baenke F, Klimova A, et al. Detecting drug
4999. resistance in pancreatic cancer organoids guides optimized
doi: 10.1111/cas.15162 chemotherapy treatment. J Pathol. 2022;257(5):607-619.
doi: 10.1002/path.5906
5. Wei L, Wen JY, Chen J, et al. Oncogenic ADAM28 induces
gemcitabine resistance and predicts a poor prognosis in 17. Halbrook CJ, Pontious C, Kovalenko I, et al. Macrophage-
pancreatic cancer. World J Gastroenterol. 2019;25(37): released pyrimidines inhibit gemcitabine therapy in
5590-5603. pancreatic cancer. Cell Metab. 2019;29(6):1390-1399.e6.
doi: 10.3748/wjg.v25.i37.5590 doi: 10.1016/j.cmet.2019.02.001
6. Thummuri D, Khan S, Underwood PW, et al. Overcoming 18. Grattarola M, Cucci MA, Roetto A, et al. Post-translational
gemcitabine resistance in pancreatic cancer using the down-regulation of Nrf2 and YAP proteins, by targeting
BCL-XL-specific degrader DT2216. Mol Cancer Ther. deubiquitinases, reduces growth and chemoresistance in
2022;21(1):184-192. pancreatic cancer cells. Free Radic Biol Med. 2021;174: 202-210.
doi: 10.1158/1535-7163.MCT-21-0474 doi: 10.1016/j.freeradbiomed.2021.08.006
7. Yu S, Wang L, Che D, et al. Targeting CRABP-II overcomes 19. Gautam SK, Basu S, Aithal A, et al. Regulation of pancreatic
pancreatic cancer drug resistance by reversing lipid raft cancer therapy resistance by chemokines. Semin Cancer Biol.
cholesterol accumulation and AKT survival signaling. 2022;86(Pt 2):69-80.
J Exp Clin Cancer Res. 2022;41(1):88. doi: 10.1016/j.semcancer.2022.08.010
doi: 10.1186/s13046-022-02261-0 20. Ning E, Turnbull G, Clarke J, et al. 3D bioprinting of mature
8. Yang G, Guan W, Cao Z, et al. Integrative genomic analysis of bacterial biofilms for antimicrobial resistance drug testing.
gemcitabine resistance in pancreatic cancer by patient-derived Biofabrication. 2019;11(4):045018.
xenograft models. Clin Cancer Res. 2021;27(12):3383-3396. doi: 10.1088/1758-5090/ab37a0
doi: 10.1158/1078-0432.CCR-19-3975 21. Wang Y, Shi W, Kuss M, et al. 3D bioprinting of breast cancer
models for drug resistance study. ACS Biomater Sci Eng.
9. Capula M, Perán M, Xu G, et al. Role of drug catabolism,
modulation of oncogenic signaling and tumor 2018;4(12):4401-4411.
microenvironment in microbe-mediated pancreatic cancer doi: 10.1021/acsbiomaterials.8b01277
chemoresistance. Drug Resist Updat. 2022;64: 100864. 22. Papaefthymiou A, Doukatas A, Galanopoulos M. Pancreatic
doi: 10.1016/j.drup.2022.100864 cancer and oligonucleotide therapy: Exploring novel

Volume 10 Issue 1 (2024) 138 https://doi.org/10.36922/ijb.1256